Skybiotech Healthcare Limited
Incorporated in 1983, Skybiotech Healthcare Ltd is in the business of Textile and Pharmaceuticals[1]
- Market Cap ₹ 29.5 Cr.
- Current Price ₹ 154
- High / Low ₹ 237 / 116
- Stock P/E
- Book Value ₹ 47.0
- Dividend Yield 0.00 %
- ROCE %
- ROE -26.4 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 3.28 times its book value
- Company has low interest coverage ratio.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Consumer Discretionary Textiles Textiles & Apparels Other Textile Products
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| 0.00 | 6.96 | 6.29 | |
| 0.12 | 9.21 | 7.98 | |
| Operating Profit | -0.12 | -2.25 | -1.69 |
| OPM % | -32.33% | -26.87% | |
| 2.00 | 0.38 | -0.03 | |
| Interest | 0.00 | 0.01 | -0.22 |
| Depreciation | 0.00 | 0.54 | 0.51 |
| Profit before tax | 1.88 | -2.42 | -2.01 |
| Tax % | 18.09% | -2.07% | |
| 1.54 | -2.37 | -1.89 | |
| EPS in Rs | 8.04 | -12.38 | -9.87 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -254% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 50% |
| 3 Years: | 57% |
| 1 Year: | -17% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -26% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 1.92 | |
| Reserves | 7.07 | |
| 7.20 | ||
| 3.91 | ||
| Total Liabilities | 20.10 | |
| 12.03 | ||
| CWIP | 0.00 | |
| Investments | 2.46 | |
| 5.61 | ||
| Total Assets | 20.10 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| -1.04 | ||
| -9.63 | ||
| 1.24 | ||
| Net Cash Flow | -9.43 | |
| Free Cash Flow | -1.37 | |
| CFO/OP | 46% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 22.03 | |
| Inventory Days | ||
| Days Payable | ||
| Cash Conversion Cycle | 22.03 | |
| Working Capital Days | -18.88 | |
| ROCE % |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Value of Quoted Investments INR ・Standalone data |
|
||||||||||
| Domestic Pharmaceutical Sales INR Lakhs |
|||||||||||
| Export Pharmaceutical Sales INR Lakhs |
|||||||||||
| Job Work Revenue (Pharmaceutical) INR Lakhs |
|||||||||||
| Pharmaceutical Subsidiary Revenue (Consolidated) INR Lakhs |
|||||||||||
| Equity Stake in Skybiotech Lifesciences Percentage ・Standalone data |
|||||||||||
Documents
Announcements
- Closure of Trading Window 30 Mar
- Result- Financial Result For Quarter Ended On December 31St, 2025 14 Feb
-
Board Meeting Outcome for Outcome Of Board Meeting To Considered And Approved Un-Audited Financials For The Quarter Ended On 31St December, 2025
14 Feb - Board approved standalone and consolidated unaudited results for quarter ended 31-Dec-2025; consolidated Q3 loss Rs48.47 lakh.
-
Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended On 31St December, 2025
11 Feb - Board meeting 14 Feb 2026 to approve unaudited Q3 results for quarter ended 31 Dec 2025.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
16 Jan - Compliance certificate Under Reg. 74(5) of SEBI (DP) Regulation, 2018 for the quarter ended on 31st December, 2025
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2008
from bse
-
Financial Year 2007
from bse
-
Financial Year 2002
from bse
Business Overview:[1]
SBHCL was engaged in the Textile business and was not generating any revenue from its main business activity. It acquired 72.52% stake in M/s. Skybiotech Lifescience Private Limited which become their subsidiary and is engaged in manufacturing Pharmaceutical Products and ingredients